House of Lords written question – answered at on 6 January 2015.
To ask Her Majesty’s Government when they expect NHS England to take a decision regarding the draft clinical commissioning policy for Duodopa.
To ask Her Majesty’s Government how NHS England's decision regarding the draft clinical commissioning policy for Duodopa will be communicated to (1) the public, (2) patient organisations, and (3) healthcare professionals.
NHS England has advised that its Clinical Priorities Advisory Group recommended that Levodopa-Carbidopa intestinal gel (Duodopa) for advanced Parkinson’s disease should not be routinely commissioned by NHS England at this time. NHS England’s Directly Commissioned Services Committee endorsed this recommendation in June 2014 and agreed that this technology should be considered further through NHS England’s prioritisation process. The decisions of the committee were communicated via a stakeholder newsletter which is accessible both via direct mail, and through the NHS England website.
Further work has been completed on NHS England’s draft clinical commissioning policy and this is now included in the prioritisation process alongside other new treatments for consideration for 2015-16.
The decision-making framework for NHS England’s prioritisation process was discussed at its Board meeting on
NHS England continues to keep the range of services and treatments available to patients under review as new evidence and expert guidance becomes available.
Yes2 people think so
No0 people think not
Would you like to ask a question like this yourself? Use our Freedom of Information site.